Abstract. Eight healthy Vietnamese male subjects received 400 mg artemisinin formulated into fatty suppositories (FS), and six different subjects received 500 mg of artemisinin formulated in polyethylene glycol suppositories (PEGS). Plasma concentrations were measured by high-performance liquid chromatography with electrochemical detection; concentration versus time curves were analyzed with nonparametric methods. No statistically significant differences were found between the two formulations. The maximum concentration (Cmax) was 100 Ϯ 102 g/L (mean Ϯ SD, range ϭ 24-330) g/L (FS), the pharmacokinetic lag time (Tlag) was 1.3 Ϯ 1.0 hr (range ϭ 0-3) (FS), and the time of the maximum concentration (Tmax) was 7.1 Ϯ 2.1 hr (range ϭ 3-10) hr (FS). Because artemisinin is not available for intravenous dosage, absolute bioavailability cannot be assessed. However, compared with a previous study on oral artemisinin in healthy Vietnamese subjects, bioavailability relative to oral administration was estimated to be approximately 30%. We conclude that therapeutic blood concentrations of artemisinin can be reached after rectal dosage. The dose after rectal administration should probably be higher than after oral administration; doubling or tripling the oral dose might be necessary, which would imply a rectal dose of at least 20 mg/kg of body weight given twice a day.
Artemisinin is a drug from a new and promising class of antimalarials. [1] [2] [3] This class includes the parent compound artemisinin, and its first-generation derivatives artemether, arteether, artesunate, and dihydroartemisinin. Clinical use in Asia for 20 years has shown that artemisinin compounds are very effective, with rapid parasite clearance, against multidrug-resistant Plasmodium falciparum. 2 It seems to be a very safe drug; to date no serious adverse effects have been reported in humans. One of the differences among these compounds is water solubility, and therefore the possibility of parenteral administration. At the present time, there is no pharmaceutical preparation of artemisinin for parenteral administration. In the treatment of severe and complicated malaria, parenteral administration of drugs is usually necessary, and rectal administration could be a feasible alternative, especially in remote areas. Although in one preliminary pharmacokinetic study very low, and probably subtherapeutic plasma concentrations were reported after rectal dosage 4 , clinical trials with artemisinin or artesunate suppositories in severe malaria have shown good results. [5] [6] [7] [8] We therefore determined the pharmacokinetics of artemisinin suppositories that are presently available in Vietnam; these suppositories have been used in recent therapeutic trials. 5, 6 The latter suppositories are fat based; we compared them with hydrophilic (i.e., polyethylene glycol)-based suppositories.
METHODS
Subjects and experimental design. Fourteen healthy male Vietnamese subjects were recruited at the Institute of Clinical Research in Tropical Medicine of the Bach Mai Hospital, Hanoi. The mean Ϯ SD characteristics of the eight subjects participating in the experiment with standard (fatty) artemisinin suppositories (FS) were age ϭ 31 Ϯ 7 years, weight ϭ 55 Ϯ 5 kg, height ϭ 163 Ϯ 6 cm, and body mass index (BMI) ϭ 20.6 Ϯ 1.5 kg·m Ϫ2 . The mean Ϯ SD characteristics of the six subjects participating in the experiment with polyethylene glycol (PEG) suppositories were age ϭ 30 Ϯ 9 years, weight ϭ 50 Ϯ 4 kg, height ϭ 163 Ϯ 9 cm, and BMI ϭ 18.9 Ϯ 1.9 kg·m
Ϫ2
. The experiment was approved by the Ethical Review Committees of the Academic Medical Center (Amsterdam) and by the Board of the Institute of Clinical Research in Tropical Medicine, Bach Mai Hospital (Hanoi). Written informed consent was obtained from all subjects prior to participation in the study. Before participation, a standard interview and physical examination were performed, and these revealed no abnormalities. Subjects arrived at 8:00 AM after an overnight fast. The suppositories were administered by the doctor supervising the experiment. The subjects remained in the hospital for 24 hr after administration, under supervision of the physician of the experimental ward during the entire study period, and they were ambulatory; eating and drinking were not restricted. There was no difference in tolerance between the two different suppositories, as far as this can be assessed by observation. We did not examine stools or gather data on stool frequency; however, no subject had diarrhea.
Artemisinin preparations and drug administration. Two types of artemisinin suppositories were used. One type had Witepsol as a fatty base. Each suppository of this type contained 200 mg of artemisinin; they were obtained from Vidipha (Ho Chi Minh City, Vietnam), and two of these were administered simultaneously. The second suppository type had a base of PEG. Each of these suppositories contained 500 mg of artemisinin; they were obtained from the Mediplantex Pharmaceutical Factory (Hanoi, Vietnam). The manufacturers gave a maximum difference of artemisinin content of Ϯ 5% of the nominal value. These two types of suppository are referred to as FS and PEGS, respectively.
Blood sampling. Blood sampling was done as described previously.
9,10 Sampling times were before dosage, and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, and 24 hours after drug administration. Ten milliliters of heparinized blood was withdrawn at each timepoint. Artemisinin assay. This was done by high-performance liquid chromatography with electrochemical detection, with a detection limit of 5 ng/ml. The method has been described in detail in previous publications. 9, 11 Data analysis. Because the concentration time profiles were not smooth (probably due to erratic absorption), a model-independent method was chosen to analyze these data. First, the area under the curve (AUC) was calculated with the trapezoidal rule. When the last concentration was not zero, extrapolation to infinity was done by dividing the last concentration by 0.27 (Kel reported by Dien and others 9 and Duc and others 10 ). The Kel (elimination rate constant) as used in all other calculations was also equated to 0.27. The area under the moment curve (AUMC) was calculated by multiplying each concentration with the time after dosage, and then calculating the area under this curve. Extrapolation to infinity was done as for the AUC. F denotes the (unknown) bioavailability. Clearance (actually Cl/F) was calculated as dose/AUC, volume of distribution (Vd [actually Vd/F]) as Cl/Kel, mean residence time (MRT) as AUMC/ AUC, and mean absorption time (MAT) as MRT Ϫ 1/Kel. All calculations were done using standard methods. 12 The maximum concentration (Cmax) and the time of the maximum concentration (Tmax) were the actually observed values. The pharmacokinetic lagtime (Tlag) was the average of the last time point with a zero concentration and the first time point with a non-zero concentration.
Statistical analysis. The Wilcoxon signed rank test was used to compare the two groups (FS and PEGS) when appropriate. Figures 1 and 2 show the concentration-time curves of all subjects for FS and PEGS, respectively. The geometric mean of these curves is indicated as a heavy line. Absorption was erratic since for many subjects the concentration time curve is not smooth; in some curves, absorption apparently follows zero-order kinetics (there is movement towards a temporary steady-state). There is large interindividual variation in drug concentrations; the variation in Cmax is approximately 10-fold. For most curves an elimination half-life cannot be calculated. We therefore took the average half-life from recent studies on similar subjects to calculate the AUC when necessary (half-life ϭ 2.57 hr, Kel 0.27/hr). 9, 10 Table 1 shows the pharmacokinetic parameters. There is approximately 50-fold (FS) and six-fold (PEGS) interindividual variation in the AUC, and thus in clearance and Vd. Given this variation, and the fact that the AUC values do not have a normal distribution, comparisons are more realistic using the geometric mean. By inspecting the geometric means of the parameters for fatty suppositories and polyethylene glycol suppositories, it appears that there are no differences; a Wilcoxon test result was nonsignificant for all comparisons. The AUC and Cmax are proportional to the dose (which differed for FS and PEGS); to compare these values, the FS values were multiplied by 1.25. The other pharmacokinetic parameters are independent of dose, and therefore could be compared without correction.
RESULTS

DISCUSSION
This is the first study that specifically addresses artemisinin pharmacokinetics after rectal administration. Contrary to a previous study in which preliminary data on rectal dosage are discussed, 4 we found that therapeutic concentrations were reached. This is in agreement with the effectiveness of rectally administered artemisinin in malaria as reported in several studies. [5] [6] [7] [8] In these studies, a rectal dosage of 400-600 mg was given twice a day for three days. When rectal administration is considered as an alternative to oral dosage, several factors are important. The first is bioavailability. We can be fairly certain that bioavailability is lower after rectal dosage. The AUC in the present study is approximately 30% of the value found after 500 mg of oral artemisinin (i.e., * AUC ϭ area under curve; Cl/f ϭ clearance; Vd/f ϭ volume of distribution; MRT ϭ mean residence time; MAT ϭ mean absorption time; Tlag ϭ pharmacokinetic lag time; Tmax ϭ time of the maximum concentration; Cmax ϭ maximum concentration; Geomean ϭ geometric mean; Mean ϭ arithmetic mean. No statistically significant differences were found in comparisons between the two groups when using a Wilcoxon test.
when the AUC from the present study is compared with the AUC of Dien and others 9 and Duc and others 10 ). This is not surprising since most drugs have a lower bioavailability after a rectal dosage than after an oral one. We can only speculate on the influence of the pharmaceutical formulation of the suppository. Having either a fatty or a polyethylene glycol base does not seem to have a major impact. The second aspect is the pattern of absorption following oral and rectal dosages. It is here that rectal artemisinin might have some advantages over oral drug administration. The pattern of absorption after oral artemisinin is first order; 9,10 this results in rapidly attained peak concentrations (Tmax ϳ 2 hr) that rapidly decrease. After rectal dosing peak concentrations are reached much later (Tmax ϳ 7 hr), are lower, and the absorption profile appears to be zero order. This can be inferred from the observation that in most subjects there is steadystate-like period. Such a phenomenon can only be observed when drug input into the body resembles a continuous, constant-rate, intravenous infusion. When comparing the concentration time profiles, rectal administration might have the advantage that after an identical dose, the concentration remains above the lowest effective concentration (which is probably in the range of 3-30 g/L)
2 for a longer time than after an oral dosage. However, the given concentration range for effectiveness is tentative, and it has not been definitively shown that the time above a certain concentration correlates better with parasite removal than the AUC or the peak concentration. A third item of importance is the concentration of the active metabolite dihydroartemisinin. The formation of this metabolite might occur at a slower rate after rectal administration, which again could result in a more effective concentration time profile. Lastly, reliability is an important issue. Interindividual variability seems to be higher after rectal administration than after an oral dosage. This causes concern because the lower concentrations after rectal dosage might easily become subtherapeutic. The fact that the studies in clinical malaria mentioned did not show a nonresponse after rectal artemisinin is reassuring. However, this is not proof that this problem will not occur (these studies included only a few dozen subjects).
Our subjects were not malaria patients. This does not affect the comparison mentioned earlier since an oral dosage has also been studied in healthy subjects. 9, 10 However, before applying these results to malaria patients, a separate study is needed. For example, a difference between patients and healthy subjects might be stool frequency. Malaria patients often have diarrhea, thus limiting the retention time in the rectum, possibly resulting in lower concentrations.
In conclusion, rectal artemisinin likely leads to effective artemisinin plasma concentrations, albeit with a wide interindividual variation. A lipophilic or hydrophilic base does not seem to make a difference. Bioavailability is 30% relative to oral dosage, and therefore the dose should probably be two-to three-fold higher; such a dosage recommendation needs experimental testing under field conditions before it can be applied generally. There is a need to study this dosage form in malaria patients for the development of other rectal formulations with possibly better bioavailability, and it might be interesting to have pharmacokinetic data on other artemisinin compounds after rectal administration. 
